Levodopa is the first-line treatment for Parkinson's disease, although the precise mechanisms mediating its efficacy remain elusive. We aimed to elucidate treatment effects of levodopa on brain activity during the execution of fine movements and to compare them with deep brain stimulation of the subthalamic nuclei. We studied 32 patients with Parkinson's disease using functional MRI during the execution of finger-tapping task, alternating epochs of movement and rest. The task was performed after withdrawal and administration of a single levodopa dose. A subgroup of patients (n = 18) repeated the experiment after electrode implantation with stimulator on and off. Investigating levodopa treatment, we found a significant interaction between both factors of treatment state (off, on) and experimental task (finger tapping, rest) in bilateral putamen, but not in other motor regions. Specifically, during the off state of levodopa medication, activity in the putamen at rest was higher than during tapping. This represents an aberrant activity pattern probably indicating the derangement of basal ganglia network activity due to the lack of dopaminergic input. Levodopa medication reverted this pattern, so that putaminal activity during finger tapping was higher than during rest, as previously described in healthy controls. Within-group comparison with deep brain stimulation underlines the specificity of our findings with levodopa treatment. Indeed, a significant interaction was observed between treatment approach (levodopa, deep brain stimulation) and treatment state (off, on) in bilateral putamen. Our functional MRI study compared for the first time the differential effects of levodopa treatment and deep brain stimulation on brain motor activity. We showed modulatory effects of levodopa on brain activity of the putamen during finger movement execution, which were not observed with deep brain stimulation.

Clinic for Cognitive Neurology University Hospital Leipzig Leipzig Germany

Department of Neurology and Center of Clinical Neuroscience 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Department of Stereotactic and Radiation Neurosurgery Na Homolce Hospital Prague Czech Republic

Max Planck Institute for Human Cognitive and Brain Sciences Leipzig Germany

Zobrazit více v PubMed

Agostino R, Berardelli A, Currà A, Accornero N, Manfredi M.. Clinical impairment of sequential finger movements in Parkinson’s disease. Mov Disord 1998; 13: 418–21. PubMed

Agostino R, Currà A, Giovannelli M, Modugno N, Manfredi M, Berardelli A.. Impairment of individual finger movements in Parkinson’s disease. Mov Disord 2003; 18: 560–5. PubMed

Akram H, Sotiropoulos SN, Jbabdi S, Georgiev D, Mahlknecht P, Hyam J, et al.Subthalamic deep brain stimulation sweet spots and hyperdirect cortical connectivity in Parkinson’s disease. Neuroimage 2017; 158: 332–45. PubMed PMC

Ashburner J, Friston KJ.. Unified segmentation. Neuroimage 2005; 26: 839–51. PubMed

Ballarini T, Růžička F, Bezdicek O, Růžička E, Roth J, Villringer A, et al.Unraveling connectivity changes due to dopaminergic therapy in chronically treated Parkinson’s disease patients. Sci Rep 2018; 8: 14328. PubMed PMC

Bäumer T, Hidding U, Hamel W, Buhmann C, Moll CK, Gerloff C, et al.Effects of DBS, premotor rTMS, and levodopa on motor function and silent period in advanced Parkinson’s disease. Mov Disord 2009; 24: 672–6. PubMed

Benabid AL, Chabardes S, Mitrofanis J, Pollak P.. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease. Lancet Neurol 2009; 8: 67–81. PubMed

Bergman H, Wichmann T, DeLong MR.. Reversal of experimental Parkinsonism by lesions of the subthalamic nucleus. Science 1990; 249: 1436–8. PubMed

Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, et al.Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 2011; 68: 165. PubMed PMC

Connolly BS, Lang AE.. Pharmacological treatment of Parkinson disease: a review. JAMA 2014; 311: 1670–83. PubMed

Eklund A, Nichols TE, Knutsson H.. Cluster failure: why fMRI inferences for spatial extent have inflated false-positive rates. Proc Natl Acad Sci USA 2016; 113: 7900–5. PubMed PMC

Fahn S. Adverse effects of levodopa in Parkinson’s disease. In: Calne DB, editor. Drugs for the treatment of Parkinson’s disease. Handbook of experimental pharmacology, vol 88. New York: Springer-Verlag Berlin Heidelberg; 1989. p. 385–409.

Fahn S. Description of Parkinson’s disease as a clinical syndrome. Ann N Y Acad Sci 2006; 991: 1–14. PubMed

Fahn S, Jankovic J, Hallett M.. Principles and practice of movement disorders E-book: expert consult. Elsevier Health Sciences; 2011. https://www.elsevier.com/books/principles-and-practice-of-movement-disorders/9781437723694.

Friston KJ, Fletcher P, Josephs O, Holmes A, Rugg M, Turner R.. Event-related fMRI: characterizing differential responses. Neuroimage 1998; 7: 30–40. PubMed

Friston KJ, Glaser DE, Henson RN, Kiebel S, Phillips C, Ashburner J.. Classical and Bayesian inference in neuroimaging: applications. Neuroimage 2002a; 16: 484–512. PubMed

Friston KJ, Penny W, Phillips C, Kiebel S, Hinton G, Ashburner J.. Classical and Bayesian inference in neuroimaging: theory. Neuroimage 2002b; 16: 465–83. PubMed

Galvan A, Devergnas A, Wichmann T.. Alterations in neuronal activity in basal ganglia-thalamocortical circuits in the parkinsonian state. Front Neuroanat 2015; 9: 5. PubMed PMC

Galvan A, Wichmann T.. Pathophysiology of parkinsonism. Clin Neurophysiol 2008; 119: 1459–74. PubMed PMC

Gountouna V-E, Job DE, McIntosh AM, Moorhead TWJ, Lymer GKL, Whalley HC, et al.Functional Magnetic Resonance Imaging (fMRI) reproducibility and variance components across visits and scanning sites with a finger tapping task. Neuroimage 2010; 49: 552–60. PubMed

Haslinger B, Erhard P, Kämpfe N, Boecker H, Rummeny E, Schwaiger M, et al.Event-related functional magnetic resonance imaging in Parkinson’s disease before and after levodopa. Brain 2001; 124: 558–70. PubMed

Herz DM, Eickhoff SB, Løkkegaard A, Siebner HR.. Functional neuroimaging of motor control in parkinson’s disease: A meta‐analysis. Hum Brain Mapp 2014; 35: 3227–37. PubMed PMC

Holiga Š, Möller HE, Sieger T, Schroeter ML, Jech R, Mueller K.. Accounting for movement increases sensitivity in detecting brain activity in Parkinson’s disease. PLoS One 2012; 7: e36271. PubMed PMC

Holiga Š, Mueller K, Möller HE, Sieger T, Schroeter ML, Vymazal J, et al.Motor matters: tackling heterogeneity of Parkinson’s disease in functional MRI studies. PLoS One 2013; 8: e56133. PubMed PMC

Holiga Š, Mueller K, Möller HE, Urgošík D, Růžička E, Schroeter ML, et al.Resting-state functional magnetic resonance imaging of the subthalamic microlesion and stimulation effects in Parkinson’s disease: indications of a principal role of the brainstem. Neuroimage Clin 2015; 9: 264–74. PubMed PMC

Hornykiewicz O. A brief history of levodopa. J Neurol 2010; 257: 249–52. PubMed

Jech R, Mueller K, Urgošík D, Sieger T, Holiga Š, Růžička F, et al.The subthalamic microlesion story in Parkinson’s disease: electrode insertion-related motor improvement with relative cortico-subcortical hypoactivation in fMRI. PLoS One 2012; 7: e49056. PubMed PMC

Jech R, Urgošík D, Tintěra J, Nebuželský A, Krásenský J, Liščák R, et al.Functional magnetic resonance imaging during deep brain stimulation: a pilot study in four patients with Parkinson’s disease. Mov Disord 2001; 16: 1126–32. PubMed

Kandel ER, Schwartz JH, Jessell TM, Biochemistry D, Jessell MBT, Siegelbaum S, et al. Principles of Neural Science. New York: McGraw-Hill; 2000.

Kraft E, Loichinger W, Diepers M, Lule D, Schwarz J, Ludolph AC, et al.Levodopa-induced striatal activation in Parkinson’s disease: a functional MRI study. Parkinsonism Relat Disord 2009; 15: 558–63. PubMed

LeWitt PA, Fahn S.. Levodopa therapy for Parkinson disease: a look backward and forward. Neurology 2016; 86(14 Suppl 1): S3–12. PubMed

Maillet A, Krainik A, Debû B, Troprès I, Lagrange C, Thobois S, et al.Levodopa effects on hand and speech movements in patients with Parkinson’s disease: a FMRI study. PLoS One 2012; 7: e46541. PubMed PMC

Michely J, Volz LJ, Barbe MT, Hoffstaedter F, Viswanathan S, Timmermann L, et al.Dopaminergic modulation of motor network dynamics in Parkinson’s disease. Brain 2015; 138: 664–78. PubMed PMC

Mink JW. The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol 1996; 50: 381–425. PubMed

Moro E, Lang AE.. Criteria for deep-brain stimulation in Parkinson’s disease: review and analysis. Exp Rev Neurother 2006; 6: 1695–705. PubMed

Mueller K, Jech R, Růžička F, Holiga Š, Ballarini T, Bezdicek O, et al.Brain connectivity changes when comparing effects of subthalamic deep brain stimulation with levodopa treatment in Parkinson’s disease. Neuroimage Clin 2018; 19: 1025–35. PubMed PMC

Nambu A, Tokuno H, Takada M.. Functional significance of the cortico–subthalamo–pallidal ‘hyperdirect’pathway. Neurosci Res 2002; 43: 111–7. PubMed

Nichols T, Hayasaka S.. Controlling the familywise error rate in functional neuroimaging: a comparative review. Stat Methods Med Res 2003; 12: 419–46. PubMed

Obeso JA, Olanow CW, Nutt JG.. Levodopa motor complications in Parkinson’s disease. Trends Neurosci; 2000; 23: S2–S7. PubMed

Pernet C, Poline J-B.. Improving functional magnetic resonance imaging reproducibility. Gigascience 2015; 4: 15. PubMed PMC

Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al.Parkinson disease. Nat Rev Dis Primers 2017; 3: 17013. PubMed

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al.MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 2015; 30: 1591–601. PubMed

Postuma RB, Dagher A.. Basal ganglia functional connectivity based on a meta-analysis of 126 positron emission tomography and functional magnetic resonance imaging publications. Cereb Cortex 2006; 16: 1508–21. PubMed

Rocchi L, Chiari L, Horak F.. Effects of deep brain stimulation and levodopa on postural sway in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002; 73: 267–74. PubMed PMC

Rowe J, Hughes L, Ghosh B, Eckstein D, Williams-Gray C, Fallon S, et al.Parkinson’s disease and dopaminergic therapy—differential effects on movement, reward and cognition. Brain 2008; 131: 2094–105. PubMed PMC

Rubchinsky LL, Kopell N, Sigvardt KA.. Modeling facilitation and inhibition of competing motor programs in basal ganglia subthalamic nucleus–pallidal circuits. Proc Natl Acad Sci USA 2003; 100: 14427–32. PubMed PMC

Singh A, Kammermeier S, Mehrkens JH, Bötzel K.. Movement kinematic after deep brain stimulation associated microlesions. J Neurol Neurosurg Psychiatry 2012; 83: 1022–6. PubMed

Singh A, Mewes K, Gross RE, DeLong MR, Obeso JA, Papa SM.. Human striatal recordings reveal abnormal discharge of projection neurons in Parkinson’s disease. Proc Natl Acad Sci USA 2016; 113: 9629–34. PubMed PMC

Tagliati M, Jankovic J, Pagan F, Susatia F, Isaias IU, Okun MS, et al.Safety of MRI in patients with implanted deep brain stimulation devices. Neuroimage 2009; 47 (Suppl 2): T53–7. PubMed

Thobois S, Dominey P, Decety J, Pollak P, Gregoire MC, Broussolle E.. Overactivation of primary motor cortex is asymmetrical in hemiparkinsonian patients. Neuroreport 2000; 11: 785–9. PubMed

Timmermann L, Braun M, Groiss S, Wojtecki L, Ostrowski S, Krause H, et al.Differential effects of levodopa and subthalamic nucleus deep brain stimulation on bradykinesia in Parkinson’s disease. Mov Disord 2008; 23: 218–27. PubMed

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE.. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 2010; 25: 2649–53. PubMed

Vingerhoets FJ, Villemure J-G, Temperli P, Pollo C, Pralong E, Ghika J.. Subthalamic DBS replaces levodopa in Parkinson’s disease: two-year follow-up. Neurology 2002; 58: 396–401. PubMed

Witt ST, Laird AR, Meyerand ME.. Functional neuroimaging correlates of finger-tapping task variations: an ALE meta-analysis. Neuroimage 2008; 42: 343–56. PubMed PMC

Wu T, Wang J, Wang C, Hallett M, Zang Y, Wu X, et al.Basal ganglia circuits changes in Parkinson’s disease patients. Neurosci Lett 2012; 524: 55–9. PubMed PMC

Yu H, Sternad D, Corcos DM, Vaillancourt DE.. Role of hyperactive cerebellum and motor cortex in Parkinson’s disease. Neuroimage 2007; 35: 222–33. PubMed PMC

Improving fMRI in Parkinson's disease by accounting for brain region-specific activity patterns

The Instrumental Activities of Daily Living in Parkinson's Disease Patients Treated by Subthalamic Deep Brain Stimulation